First Patient Dosed in Ph 1 Combo Cohort of MEM-288 + Docetaxel in Advanced NSCLC
“Dosing the first patient in this combination cohort marks an important milestone for the MEM-288 program,” said Mark Cantwell, Ph.D., Chief Scientific Officer, Memgen. “Docetaxel remains a backbone in the second-line setting, yet outcomes are still disappointing, with median overall survival typically less than one year. Combining intratumoral MEM-288 with chemotherapy has strong biological rationale. Our goal with this study is to improve the depth and durability of response and, ultimately, deliver a clinically meaningful improvement over the current standard of care for patients facing significant unmet need.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.